Total amount: € 0,00
A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413
Online ISSN 1827-1936
Stefani P. M. 1, Salvadori U. 1, Gottardi M. 1, Bissoli S. 2, Chierichetti F. 2, Gherlinzoni F. 1
1 Hematology Unit, General Hospital Hospital, Treviso;
2 Nuclear Medicine Unit, General Hospital, Castelfranco Veneto
AIM: Positron Emission Tomography/Computed Tomography (PET/CT scan) has increasingly been used for management of lymphoma, however few and conflicting data have been provided in the setting of high dose therapy with autologous stem cell transplantation (ASCT) so far.
METHODS: We retrospectively evaluated the outcome of 47 NHL patients who underwent ASCT for relapsed/refractory disease or high risk disease or partial response after first line treatment, with the aim of testing sensitivity, specificity, positive and negative prognostic value of PET/CT performed before and after ASCT.
RESULTS: In our experience pre ASCT-PET/CT predicts outcome of Non Hodgkin’s Lymphoma patients with chemosensitive relapse, whereas post ASCT-PET showed a better prognostic value for relapsed disease.
CONCLUSIONS: Results of our study, if confirmed by studies on a larger scale, could significantly contribute to design future trials and optimise the management of lymphoma patients.